Adocia: Successful Phase 3 in China for BioChaperone Lispro, $20M in Sight
On Monday, during the annual scientific conference of the American Diabetes Association, Adocia presented the complete data from its phase 3 trial conducted in China with BioChaperone Lispro for type 2 diabetes. This presentation confirmed the positive conclusions previously announced in July 2025.
Confirmed Non-Inferiority with Targeted Clinical Benefits
The THDB0206L02 study, which involved more than 1,000 type 2 diabetes patients, confirmed the non-inferiority of BioChaperone Lispro in reducing HbA1c across the population. Its safety profile proved equivalent to that of Humalog, the reference treatment developed by Eli Lilly.
Beyond these primary endpoints, Adocia's ultra-rapid insulin demonstrated better glycemic control in patients on metformin or those with levels below 8.5%. The trial also highlighted improved glycemic control throughout the day and after each meal for the entire population studied.
A Candidate Advancing Towards Regulatory Development in China
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
BioChaperone Lispro was licensed to Tonghua Dongbao in 2018 for China and other Asian countries. The Chinese partner is currently preparing to file for marketing authorization in China, under its responsibility. According to the licensing agreement, Adocia will receive a milestone payment of $20 million upon approval, as well as double-digit royalties on future sales.
A Virtual Event to Detail the Data
Adocia is organizing a virtual event on June 16, 2026, at 10 AM EST (4 PM CEST) with Dr. Tim Heise, lead researcher, chairman of the board, and co-founder of the Profil research institute based in Neuss, Germany, specializing in early-phase studies on diabetes treatments. Olivier Soula, CEO and co-founder of Adocia, along with You-Ping Chan, head of R&D, will discuss the detailed results of the phase 3 trial.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 0 millions d'euros
Quarterly revenue: 0 millions d'euros
Revenue growth: -97 %
Guidance from the release
« Au 30 septembre 2026, la Société disposait d'une trésorerie de 8,4 millions d'euros qui lui permettait de financer ses activités jusqu'au début du deuxième trimestre 2027 » ; « Cette opération, en prenant en compte l'utilisation complète de la convention d'avance en compte courant, ainsi que la réduction des coûts initiée par la Société depuis septembre 2026, permet d'étendre l'horizon de trésor
Risks mentioned
Dépendance critique au paiement d'étape de 20 millions de dollars conditionné à l'obtention de l'AMM de BioChaperone Lispro en Chine
Besoin de financement à court ou moyen terme et capacité à lever des fonds supplémentaires
Incertitudes des données cliniques futures et de l'évolution des marchés du diabète et de l'obésité
Opportunities identified
Paiement d'étape de 20 millions de dollars sous condition de l'approbation de BC Lispro en Chine avec redevances à deux chiffres
Accords de collaboration R&D monétisés avec les entreprises pharmaceutiques pour tester librement la technologie BioChaperone
Extension de l'horizon de trésorerie jusqu'au T1 2028 (voire 2029 si AMM obtenue) grâce à la levée de 7 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
